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ABSTRACT
Objective: Nosocomial infections or Hospital acquired infection (HAI) are one of the major threats to hospitalized patients as well as for the hospital 
associated personnel. In last few years there is a gross change in causative agents, new organisms have come out with great threat to hospitals as they 
possess antibiotic resistance property e.g. production of biofilm, production of enzymes such as β- lactamases. Among many organisms, Acinetobacter 
baumannii has emerged as a potent nosocomial pathogen. Our objective of this study was to find the burden of Acinetobacter baumannii infections 
which are associated as nosocomial infections and to determine the drug of choice for an effective treatment.
Methods: Clinical specimens were collected from patients of different unit of the hospital by maintaining universal precautions and standard 
microbiological protocols. All the respective specimens were cultured in respective culture medium i.e. MacConkey agar, blood agar, chocolate agar, 
cysteine lactose electrolyte deficient (CLED) agar and, fluid thioglycolate (TG) medium at 37˚C for 24-48 hours. After incubation of 24-48 hours culture 
plates were examined for bacterial growth and identification and antibiotic sensitivity test was made by Vitek2 compact.
Result: The study was conducted at the department of microbiology from January 2016 to April 2016. A total of 2582 specimens were collected and 
processed for identification and sensitivity testing. Specimens of all age group (2 days- 93 years) and both sexes were processed for identification 
of A. baumannii and antibiotic sensitivity testing. A total of 119 isolates (4.60%) of A. baumannii were obtained from 2582 clinical specimens. The 
most common infection A. baumannii was found as lower respiratory tract infection (89.07%) followed by abscess (6.72%), septicaemia (2.52%), 
urinary tract infections (0.84%), and soft tissue infections (0.84%). The maximum sensitivity of A. baumannii isolates were seen to Colistin (CL) (119, 
100%), followed by Tigecycline (TGC) (63, 52.94%) and Minocycline (MIN) (27, 22.69%). The maximum resistant was observed for Imipenem (IMI), 
Aztreonam (AZT) and Ticarcillin- clavulanic acid (TIC) (119, 100%).
Conclusion: The Gram- negative coccobacillus, Acinetobacter baumannii poses a formidable threat to patients. It has emerged as a superbug in 
hospital environment particularly in ICU units. The chances of A. baumannii infections increase in the presence of iatrogenic factors like inadequate 
long- term antibiotic therapy and new interventions in a medical facility. To control the burden of Acinetobacter infections new therapies such 
as combine therapy must be obtained and followed with proper dose as recommend by physicians; along with awareness of the importance of 
this infection should be implicated. Proper sanitation, good housekeeping, sterilization of equipment, hand hygiene, water purification, isolation 
procedures and maintaining of the hospital environment, use of infection control practices are some of the measures to control the transmission of 
Acinetobacter spp. among hospital personnel.
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INTRODUCTION
Hospital acquired infection (HAI) also called nosocomial infection is a 
kind of infection which is acquired in the hospital by a patient in whom 
the infection was not present at the time of admission but emerged 
after discharging and it also includes occupational infections among 
the staff of the organization [1,2]. Nosocomial infections are mostly 
caused by Gram-negative organisms and are one of the major issues in 
patient safety. HAIs are one of the major causes of death [3] which have 
worldwide prevalence and affect developed, developing and resource-
poor countries. The rate of morbidity and mortality is significantly 
increased and cause financial losses for health-care system. The study 
has revealed that within hospital it is mostly prevalent is intensive 
care units (ICU) followed by acute surgical and orthopedic wards [4], 
approximately 30% patients in ICU are affected by at least one 
nosocomial infection [5]. Acinetobacter is Gram-negative coccobacillus, 
who has become the most prevalent cause of HAI. It has been identified 
to cause sporadic infections in health-care settings and has a significant 
role in colonization in critically ill patients [6]. The species Acinetobacter 
are associated with healthcare-related outbreaks [7-9]. Advance 
medical interventions and various surgical procedures increase the 
rate of nosocomial infections. Among all species of Acinetobacter, 
Acinetobacter baumannii has been found to cause approximately 
80% of reported Acinetobacter infections [10]. Their rapid ability to 
acquire resistant genes, minimal nutritional requirement, adherence to 
inanimate objects and long-term survival on them, biofilm production 
made them a successful nosocomial pathogen that is associated 
with respiratory tract infections, abscesses, bloodstream infections, 
meningitis, urinary tract infections, pleural effusion, etc. They 
resist mostly all common antibiotics through a number of different 
mechanisms which includes production of enzymes (β-lactamases, 
aminoglycosides-modifying enzymes), alteration in outer membrane 
proteins and penicillin-binding proteins, efflux pumps, e.g., multidrug 
efflux pump, i.e., AdeABC, MATE pump AdeM, Tet (A), and Tet (B). Lower 
respiratory tract infections were more prevalent (89.07%) in hospital 
facility followed by abscess (6.72%), septicemia (2.52%), urinary tract 
infections (0.84%), and soft tissue infections (0.84%). Males were 
most commonly affected with Acinetobacter infections (64.70%) when 
compared with females (35.30%). A more frequent visit to the hospitals 
might be the possible cause of infections for the males [11]. Colistin 
was the most promising drug followed by tigecycline and minocycline. 
Imipenem, aztreonam, and ticarcillin-clavulanic acid were most 
resistant. Good housekeeping, sterilization of equipment, hand hygiene, 
water purification, isolation procedures and maintaining of the hospital 
environment, use of infection control practices should be implemented 
to control the rate A. baumannii infection.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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The study was conducted at the department of microbiology from 
January 2016 to April 2016. A total of 2582 clinical specimens were 
collected from patients of different unit of the hospital by maintaining 
universal precautions and standard microbiological protocols. The 
specimens include lower respiratory tract samples, i.e., endotracheal 
secretions, tracheal secretions, bronchoalveolar lavage, sputum, 
bronchial wash, and endotracheal tract tips, pus and pus swabs, blood, 
cerebrospinal fluid, pleural fluid, ascitic fluid, and tissues. All specimens 
were cultured on MacConkey agar and sheep blood agar (except 
Fig. 1: Distribution of Acinetobacter baumannii infections
Fig. 2: Effect of antibiotics on Acinetobacter baumannii isolates
Table 1: Gender wise distribution of A. baumannii infections
Gender Total cases Positive cases
n (%)
Male 1718 77 (64.70)
Female 864 42 (35.30)
Total 2582 119 (100)
A. baumannii: Acinetobacter baumannii
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urine, it was inoculated on cystine lactose electrolyte deficient agar) 
and incubated at 37°C for 24-48 hrs. On MacConkey agar nonlactose 
fermenter colonies were obtained with faint pink color due to oxidation 
of lactose by the organism. Translucent to opaque convex colonies were 
obtained on sheep blood agar. On cystine lactose electrolyte deficient 
agar colonies were blue in color. The colonies were further tested for 
oxidase which was negative. The identification and sensitivity were 
done by Vitek2 compact which is based on advanced colorimetry and 
MIC technique, respectively.
A total of 2582 specimens were collected and processed for identification 
and sensitivity testing. Specimens of all age group (2 days-93 years) 
and both sexes were processed for identification of A. baumannii 
and antibiotic sensitivity testing. A total of 119 isolates (4.60%) of 
A. baumannii were obtained from 2582 clinical specimens. The most 
common infection A. baumannii was found as lower respiratory tract 
infection (89.07%) followed by abscess (6.72%), septicemia (2.52%), 
urinary tract infections (0.84%), and soft tissue infections (0.84%) 
(Fig. 1).
Out of 2582 specimens processed 1718 (66.54%) were from male 
with positive A. baumannii infections 77 (64.70%) and 864 (33.46%) 
specimens were from female with 42 (35.30%) positive A. baumannii 
infections. Males (64.70%) were more commonly infected with 
A. baumannii than females (35.30%) (Table 1).
The maximum sensitivity of A. baumannii isolates were seen to colistin 
(119, 100%), followed by tigecycline (63, 52.94%) and minocycline 
(27, 22.69%) whereas the sensitivity to cefoperazone-sulbactam 
was 11.8%. Isolates were appeared to be intermediately sensitive 
to tigecycline (35, 29.41%), cefoperazone-sulbactam (34, 28.6%), 
minocycline (16, 13.45%), and ceftazidime (1, 0.84%). The maximum 
resistant was observed for imipenem, aztreonam, and ticarcillin-
clavulanic acid (119, 100%), followed by ciprofloxacin (118, 99.16%), 
meropenem (118, 99.16%), piperacillin-tazobactam (117, 98.32%), 
cefepime (117, 98.32%), doripenem (117, 98.32%), gentamicin 
(117, 98.32%), and levofloxacin (117, 97.48%) (Fig. 2).
A. baumannii is Gram-negative coccobacillus that has emerged as a 
successful nosocomial pathogen in past two decades. Its ability to resist 
drug, minimal nutrition requirements and ubiquitous distribution in 
nature made it a superbug. They are ubiquitous inhabitants of soil, water, 
and sewage environments. It is a commensal flora of human and animal 
skin that eases its transmission to critically ill patients in a hospital 
facility. Advance facilities in treatment and use of broad-spectrum 
antibiotic therapy increases the rate of morbidity and mortality of 
Acinetobacter infections. Acinetobacter adheres to surfaces and survives 
for a long time on surfaces of inanimate substances which play a key role 
in their pathogenesis. They are a strong producer of biofilm which helps 
them in trapping and concentrating all essential requirements from the 
environment and also provide a gate for horizontal gene transfer. Their 
ability of rapid acquiring genes that encoded drug resistant property 
has made them a potent pathogen in a hospital environment. Biofilm 
prevents bacteria from host immune defense and also diminish the 
action of antibiotics. The ratio of multi-drug resistant A. baumannii is 
increased, particularly in ICU patients [12]. In last two decades, the 
incidence of Acinetobacter infections has increased at a high rate that 
made them be ranked as 2nd most common nosocomial pathogen found 
in all clinical specimens after Pseudomonas aeruginosa and 4th according 
to the frequency of infections after P. aeruginosa, Staphylococcus aureus, 
and Klebsiella pneumoniae [13].
In this study, a total of 119 (4.60%) A. baumannii isolates were isolated 
using Vitek2 compact from a total of 2582 processed clinical specimens 
including lower respiratory samples, blood, urine, body fluids, and 
tissues. Respiratory tract infections (89.07%) were most common 
infection observed followed by abscess (6.72%), septicemia (2.52%), 
urinary tract infections (0.84%), and soft tissue infections (0.84%) 
(Figure 1). The reason for the respiratory infections to be more frequent 
is may be because of the use of mechanical ventilators and intubations. 
Tripathi et al. reported a total number of 107 (1.02%) Acinetobacter 
isolates from all processed clinical specimens and Mal-Warid and 
Thahab reported 11 (2.40%) isolates of A. baumannii from a total of 
458 clinical samples which is well comparable with our study.
In this study, A. baumannii infections were common in males (64.70%) 
as compared with females (35.30%). A more frequent visit to the 
hospitals might be the possible cause of infections for the males [11].
The notorious nature of A. baumannii to acquire resistant genes is 
accounting for drug resistance to most common antibiotics. This 
has created a major challenge in patient safety. Acinetobacter spp. is 
universally resistant to penicillin, ampicillin, and cephalothin. [11]. 
Acinetobacter resists mostly all the classes of drug including 
β-lactams, aminoglycosides, quinolones, and tetracyclines. Through 
the production of enzymes (β-lactamases, aminoglycosides-modifying 
enzymes), changes in their OMPs, using of multidrug efflux pumps 
and alteration in the affinity or expression of PBPs Acinetobacter spp. 
resist β-lactams and carbapenems. In this study, IMI, azidothymidine, 
and TIC have shown maximum resistant (100%) followed by CIP 
(99.16%), MER (99.16%), PT (98.32%), CPM (98.32%), DOR (98.32%), 
GEN (98.32%), and LEV (97.48%). Colistin was the most sensitive drug 
(100%) obtained. Sensitivity to tight glycemic control (TGC) and MIN 
was 52.94% and 22.69%, respectively. Isolates were appeared to be 
intermediately sensitive to TGC (29.41%), CFS (28.6%), MIN (13.45%), 
and CAZ (0.84%). Development of new therapies, well-managed clinical 
trials of existing antibiotics for combination therapy, prevention of 
transmission of the hospital-associated infections, hospital hygiene are 
essential to control Acinetobacter infections.
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